India Pharma Outlook Team | Monday, 28 July 2025
In a remarkable boost for innovation in antibiotics, Wockhardt's Zaynich has been mentioned in a top medical journal in the UK following a remarkable recovery case of a liver transplant patient with a pan-drug-resistant infection.
The combination of Cefepime and Zidebactam, has shown a possible FDA breakthrough therapy and is one of very few that may potentially work against multi-drug resistant bacteria.
The published case report illustrates the compassionate use of Zaynich in a U.S. patient who had both Pseudomonas and Klebsiella, that each contained four different resistance mechanisms. Previous treatments, including some of the most advanced antibiotics like cefiderocol and imipenem/relebactam, had failed. Remarkably, after just 14 days using Zaynich, the patient was deemed infection free and stable enough to start chemotherapy.
Also Read: How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants
Zaynich has therefore been well supported by clinical data, and following completion of a global Phase III trial, its composite cure rate of 89% was significantly above meropenem. In addition to that, Zaynich has been used in over 50 extremely ill patients, under compassionate use protocols, with encouraging success.
In terms of the industry, this mention in international medical literature along with the clinical results adds essential credibility as Wockhardt looks to submit for regualtory approval in the US, EU and India. With a global antibiotic resistance crisis mounting, Zaynich is targeting a $9 billion market opportunity, making it one of the most closely watched candidates in Wockhardt’s pipeline.
As regulatory filings move forward, today’s recognition marks a pivotal moment for Zaynich’s commercial and clinical trajectory—and a renewed hope in the fight against drug-resistant infections.
